Neurona Therapeutics Completes Clinical Enrollment of First Cohort and Updates on Long-lasting Impact in First Patients Treated in Ongoing Phase I/II Trial of NRTX-1001 Cell Therapy for Drug-resistant Focal Epilepsy
19 oct. 2023 08h00 HE
|
Neurona Therapeutics
First cohort treated in Ph I/II clinical trial of NRTX-1001 in adults with focal epilepsy, update on first patients'progress
Neurona Therapeutics Announces Participation in Upcoming Investor Conferences in October
10 oct. 2023 16h01 HE
|
Neurona Therapeutics
Neurona Therapeutics CEO to participate in October Investor Conferences
Neurona Therapeutics Announces Publication in Cell Stem Cell Reporting the Development of Investigational Novel Regenerative Cell Therapy Strategy for Drug-resistant Focal Epilepsy
05 oct. 2023 11h00 HE
|
Neurona Therapeutics
Publication of preclinical studies supporting ongoing open-label first-in-human Phase I/II trial of cell therapy for drug-resistant focal epilepsy
Neurona Therapeutics Appoints James Stutz as Chief Financial Officer and Chief Business Officer
31 juil. 2023 08h00 HE
|
Neurona Therapeutics
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological...
Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy
15 juin 2023 11h05 HE
|
Neurona Therapeutics
Promising reduction (>95%) in seizure frequency at the key one-year post treatment endpoint in the first patient to receive NRTX-1001, memory improvements, and seizure-freedom since seven-months...
Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting
24 avr. 2023 08h00 HE
|
Neurona Therapeutics
NRTX-1001 administration is well-tolerated with continued seizure reduction of >90% in the first two patients at nine- and five-months post-treatment, respectively Impaired-awareness seizures...
Neurona Therapeutics Announces Presentation at the Oppenheimer 33rd Annual Healthcare Conference
08 mars 2023 16h01 HE
|
Neurona Therapeutics
SAN FRANCISCO, March 08, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders,...
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy
14 févr. 2023 08h00 HE
|
Neurona Therapeutics
NRTX-1001 administration is well-tolerated and shows seizure reduction of >90% in the first two patients at six- and three-months post-treatment, respectively Data & Safety Monitoring Board...
Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting
05 déc. 2022 08h00 HE
|
Neurona Therapeutics
NRTX-1001 administration was well-tolerated, with notable seizure reduction reported in early data from the first two patients in Phase I/II clinical trial Additional preclinical data highlight...
Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data
21 nov. 2022 08h00 HE
|
Neurona Therapeutics
Early data from the first two patients treated with NRTX-1001 report a trend toward seizure suppression and that administration of the cell treatment has been well-tolerated thus far Pioneering cell...